Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

TC BioPharm (Holdings) plc - American Depositary Shares (NQ: TCBP )

0.6560 +0.0360 (+5.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TC BioPharm (Holdings) plc - American Depositary Shares

InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Receives $250,000 Grant to Enhance TCB008 Manufacturing Efficiency
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Updates Shareholders on Major Milestones, Expands Clinical Trial Sites and Secures $8M Funding in 2024
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Collaboration for Monkeypox Treatment Development
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Newly Opened London-Based ACHIEVE UK Trial Site Amid ‘Very Positive’ Study Progression
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient
Via Investor Brand Network
InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Marks Milestone as First Patient Completes Full Dose in ACHIEVE Trial with No Adverse Events
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox
Via Investor Brand Network
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial
Via Investor Brand Network
TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 6, 2023) - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ: TCBP) ("the... 
Via Newsfile
Exposures Product Safety
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
EQNX::TICKER_START (NASDAQ:TCBP) EQNX::TICKER_END 
Via FinancialNewsMedia
TC BioPharm Ltd ($TCBP) leads fight against Acute myeloid leukemia with its cell therapy product OmnImmune
Via AB Newswire
Topics Death Economy Stocks
Exposures COVID-19 Death Interest Rates
InvestorNewsBreaks – TC Biopharm PLC (NASDAQ: TCBP) Closes on $17.5M Public Offering
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.